相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability
Young Nam Kwon et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)
Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy
Yoshiki Takai et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder
Tetsuya Akaishi et al.
NEUROLOGY (2021)
Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis
John J. Chen et al.
CURRENT OPINION IN NEUROLOGY (2020)
Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence
Tetsuya Akaishi et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes
Maria Isabel Leite et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No
Alvaro Cobo-Calvo et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
Jyh Yung Hor et al.
FRONTIERS IN NEUROLOGY (2020)
Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders
Tetsuya Akaishi et al.
SCIENTIFIC REPORTS (2020)
Retire statistical significance
Valentin Amrhein et al.
NATURE (2019)
Treatment of neuromyelitis optica spectrum disorders
Andrew R. Romeo et al.
CURRENT OPINION IN RHEUMATOLOGY (2019)
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
S. J. Pittock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis
Deena A. Tajfirouz et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2019)
MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder
Giordani Rodrigues dos Passos et al.
FRONTIERS IN NEUROLOGY (2018)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?
Franziska Di Pauli et al.
FRONTIERS IN IMMUNOLOGY (2018)
Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders
Alexis Montcuquet et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders
Alexis Montcuquet et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study
Hadas Stiebel-Kalish et al.
PLOS ONE (2017)
Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later
Sean J. Pittock et al.
SPECIAL ISSUE: THE YEAR IN NEUROLOGY AND PSYCHIATRY (2016)
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
Ingo Kleiter et al.
NEUROTHERAPEUTICS (2016)
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients
Florence Pache et al.
JOURNAL OF NEUROINFLAMMATION (2016)
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
Sven Jarius et al.
JOURNAL OF NEUROINFLAMMATION (2016)
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk et al.
NEUROLOGY (2015)
Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder
Marius Ringelstein et al.
JAMA NEUROLOGY (2015)
Aquaporin-4 autoimmunity
Anastasia Zekeridou et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
Patrick Waters et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
Corinna Trebst et al.
JOURNAL OF NEUROLOGY (2014)
Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK
Liene Elsone et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Douglas Kazutoshi Sato et al.
NEUROLOGY (2014)
Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorder
So-Young Huh et al.
JAMA NEUROLOGY (2014)
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder
Su-Hyun Kim et al.
JAMA NEUROLOGY (2013)
Neuromyelitis optica
Dean M. Wingerchuk et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2008)
Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre
Toshiyuki Takahashi et al.
BRAIN (2007)
Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica
T Misu et al.
NEUROLOGY (2005)
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
VA Lennon et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
分享论文
